Table 2.
Univariate logistic regression model.
| baseline characteristics | CR (3months) | ORR (3months) | PFS | OS | ||||
|---|---|---|---|---|---|---|---|---|
| Odds ratio | P | Odds ratio | P | Odds ratio | p | Odds ratio | p | |
| Age (<60/≥60)y | 0.997 | 0.978 | 1.029 | 0.622 | 0.997 | 0.955 | 1.037 | 0.544 |
| Sex (male/female) | 0.133 | 0.113 | 0.300 | 0.344 | 0.200 | 0.203 | 0.300 | 0.344 |
| ECOG (2-3/0-1) | -2.367 | 0.070 | 0.025 | 0.016 | ------ | ------ | 40.00 | 0.016 |
| CSF involvement (+/-) | 0.313 | 0.978 | 0.150 | 0.172 | ------ | ------ | 6.667 | 0.172 |
| BM involvement (+/-) | 1.500 | 0.697 | 4.000 | 0.223 | 0.429 | 0.428 | 0.857 | 0.889 |
| block size≥5cm (+/-) | ------ | ------ | ------ | ------ | ------ | ------ | 15.00 | 0.051 |
| CART infusion dose* | 3.144 | 0.978 | 4.000 | 0.223 | 0.513 | 0.271 | 0.782 | 0.672 |
| PB tumor cell** (+/-) | 2.625 | 0.383 | 6.750 | 0.112 | 0.250 | 0.223 | 0.5625 | 0.613 |
* CART infusion dose every increase 1 x 10 ^ 6 / kg; **Whether tumor cells were still present in peripheral blood at the time of lymphocyte collection.